TY  - JOUR
AU  - Alves, D
AU  - Curvello, R
AU  - Henderson, E
AU  - Kesarwani, V
AU  - Walker, JA
AU  - Leguizamon, SC
AU  - McLiesh, H
AU  - Raghuwanshi, VS
AU  - Samadian, H
AU  - Wood, EM
AU  - McQuilten, ZK
AU  - Graham, M
AU  - Wieringa, M
AU  - Korman, TM
AU  - Scott, TF
AU  - Holl, MMB
AU  - Garnier, G
AU  - Corrie, SR
Y2  - 2020/12/16
Y1  - 2020/08/28
SN  - 2379-3694
UR  - http://hdl.handle.net/11343/254377
AB  - High-throughput and rapid serology assays to detect the antibody response specific to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in human blood samples are urgently required to improve our understanding of the effects of COVID-19 across the world. Short-term applications include rapid case identification and contact tracing to limit viral spread, while population screening to determine the extent of viral infection across communities is a longer-term need. Assays developed to address these needs should match the ASSURED criteria. We have identified agglutination tests based on the commonly employed blood typing methods as a viable option. These blood typing tests are employed in hospitals worldwide, are high-throughput, fast (10-30 min), and automated in most cases. Herein, we describe the application of agglutination assays to SARS-CoV-2 serology testing by combining column agglutination testing with peptide-antibody bioconjugates, which facilitate red cell cross-linking only in the presence of plasma containing antibodies against SARS-CoV-2. This simple, rapid, and easily scalable approach has immediate application in SARS-CoV-2 serological testing and is a useful platform for assay development beyond the COVID-19 pandemic.
LA  - English
PB  - AMER CHEMICAL SOC
T1  - Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans
DO  - 10.1021/acssensors.0c01050
IS  - ACS Sensors
VL  - 5
IS  - 8
SP  - 2596-2603
ER  -